Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Viridian Therapeutics Inc VRDN

Healthcare Biotechnology
Viridian Therapeutics, Inc. is a biopharmaceutical company focused on engineering and developing potential medicines for patients with serious and rare diseases. The Company is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The Company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:VRDN)

Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data

Business Wire 10 days ago

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire November 5, 2024

Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock

Business Wire September 11, 2024

Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock

Business Wire September 10, 2024

Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease

Business Wire September 10, 2024

Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024

Business Wire September 9, 2024

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire September 5, 2024

Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results

Business Wire August 8, 2024

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire August 7, 2024
View More News ››

Opinion & Analysis (NDAQ:VRDN)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:VRDN)

Trading (VRDN) With Integrated Risk Controls

NEWS: $VRDN Trading (VRDN) With Integrated Risk Controls2024-09-23 03:14:00 ET Stock Traders Daily has produced this trading report...
whytestocks - September 23, 2024

VRDN Price Target Alert: $44.00. Issued by RBC Capital

News; $VRDN VRDN Price Target Alert: $44.00. Issued by RBC Capital2024-09-13 09:00:07 ET Gregory Renza from RBC Capital issued a price...
whytestocks - September 13, 2024

Trend Tracker for (VRDN)

News; $VRDN Trend Tracker for (VRDN)2024-09-12 08:20:00 ET Stock Traders Daily has produced this trading report using a proprietary...
whytestocks - September 12, 2024

Viridian Therapeutics: Advancing Innovative Therapies for Th

http://beyondspx.com/2024/08/01/viridian-therapeutics-advancing-innovative-therapies-for-thyroid-eye-disease-and-autoimmune-disorders/
MikeTester - August 1, 2024

Outperform Recommendation Issued On VRDN By RBC Capital

Breaking News: $VRDN Outperform Recommendation Issued On VRDN By RBC Capital2024-06-11 14:30:05 ET RBC Capital analyst issues OUTPERFORM...
whytestocks - June 11, 2024

head & shoulders formation completed

watching this one for a possible buy order,so glta.
coolfooldumbguy - February 18, 2020
View more Bullboard ››

Calima Energy Ord Shs

Calima Energy Ord Shs

Calima Energy Limited is an Australia-based production-focused energy company. The Company is engaged in the exploration and ...
View More »